Clinical trials: Pulmonary Fibrosis, open to volunteers
Cystic Fibrosis, Congenital Bilateral Absence of Vas Deferens
Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation
The aim of this observational study is to better understand the role and involvement of the regulatory elements of the CFTR gene, with the aim of better describing the 3D organisation of chromatin at the CFTR locus in epididymal…
- Conditions
- Cystic Fibrosis, Congenital Bilateral Absence of Vas Deferens, Sterility, Male
- Trial name
- CFTR-EP (NCT06045702)
- Testing
- Epididymal sample
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Cystic Fibrosis, Pancreatic Insufficiency
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop.
- Trial name
- NCT01851694
- Testing
- GLP-1, GIP
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Pulmonary Function
A National Registry on Chinese Patients With Cystic Fibrosis
Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians.
- Trial name
- NCT05289245
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Cystic Fibrosis
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
This is a 3-part, single-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part A) and multiple-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy…
- Trial name
- ABCI (NCT05802264)
- Testing
- ABCI
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Cystetic Medicines, Inc.
Pulmonary Fibrosis
Advanced Imaging for Pulmonary Fibrosis
The purpose of this study is to determine if measurements of active collagen deposition using [68Ga]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)…
- Trial name
- NCT06532071
- Testing
- [68Ga]CBP8, Gadoterate Meglumine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Peter Caravan
Idiopathic Pulmonary Fibrosis
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose ([18F] FDG) and fluorine-18 Displacement Per Atom ([18F]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung…
- Trial name
- NCT04362644
- Testing
- PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis
New Diagnostic Approaches in the Management of Inflammatory Lung Diseases
Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are major causes of morbidity and mortality worldwide.
- Trial name
- ALPI (NCT07723638)
- Testing
- Integrated Precision Medicine Platform
- Volunteers
- 200 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Fibrotic Interstitial Lung Disease, IPF and PPF
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data…
- Conditions
- Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
- Trial name
- RESPOND-ILD (NCT07673237)
- Testing
- Spirometer, Oximeter, Scale
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Idiopathic Pulmonary Fibrosis (IPF)
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic…
- Trial name
- SURPASS-IPF (NCT07284602)
- Testing
- Deupirfenidone, Pirfenidone (PFD)
- Where
- 18 sites in United States, Canada
- Volunteers
- 1,100 people
- Sponsor
- PureTech
Lung Fibrosis
Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control Study
Chronic obstructive pulmonary disease (COPD) is frequently accompanied by airway mucus plugs, which are closely associated with airflow obstruction, acute exacerbations, and increased mortality.
- Trial name
- NCT07236541
- Testing
- No intervention; observational biospecimen collection only
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ming Zhong
Idiopathic Pulmonary Fibrosis
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
- Trial name
- NCT05571059
- Testing
- Ifetroban Sodium
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- Cumberland Pharmaceuticals
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Cystic Fibrosis (CF), New Diagnostics
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with…
- Trial name
- SEND-CF (NCT07312734)
- Where
- 9 sites in United States
- Volunteers
- 300 people
- Sponsor
- Chris Goss
COPD, Interstitial Pneumonia
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
This study analyzes patients who underwent lung transplantation at the First Affiliated Hospital of Zhejiang University from 2017 to 2024, focusing on anesthesia's impact on post-op results.
- Conditions
- COPD, Interstitial Pneumonia, Bronchiectasis, Respiratory Failure
- Trial name
- NCT06922916
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Zhejiang University
Severe Asthma, COPD
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with muco-obstructive pulmonary disease.
- Conditions
- Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
- Trial name
- NCT06985225
- Testing
- Hyperpolarized 129 Xenon
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Kansas Medical Center
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute